Glaxosmithkline Biologicals Sa

Novartis Ag

Universiteit Leiden

Novartis Vaccines and Diagnostics Srl

Seqirus UK Limited

O'hagan, Derek

Barbara Baudner

Derek T O'Hagan

Manmohan Singh

Giuseppe Del Giudice

Simone Bufali

David Skibinski

Sushma Kommareddy

Simona Gallorini

Giuseppe Del Guidice

David Ag Skibinski

Amanda Scampini

Derek Thomas O'HAGAN

The invention improves TdaP vaccines by including a TLR agonist in them. This agonist can provide stronger protection, longer-lasting protection, and/or can reduce the amount of antigen which is required to achieve a particular immune response.

Adjuvanted formulations of booster vaccines

Combination vaccine compositions as well as methods for their manufacture have a relatively low amount of antigen and/or a relatively low amount of aluminium, but they can nevertheless have immunogenicity which is comparable to combination vaccines with a relatively high amount of antigen and/or a relatively high amount of aluminium. Aluminium-free combination vaccine compositions are also provided e.g. compositions which are adjuvanted with an oil-in-water emulsion adjuvant.

Combination vaccines with lower doses of antigen and/or adjuvant

An intradermal delivery system comprises an immunogenic composition comprising a TLR agonist and immunogen and a microneedle. The immunogenic composition may comprise a solid biodegradable microneedle or a solid coated microneedle. The intradermal delivery system may be formulated into a skin patch.

Intradermal delivery of immunological compositions comprising toll-like receptor 7 agonists

Serogroup B meningococcus antigens can successfully be combined with diphtheria, tetanus and pertussis toxoids ('DTP') to provide effective combination vaccines for protecting against multiple pathogens. These combinations are effective with a range of different adjuvants, and with both pediatric-type and booster-type DTP ratios. The adjuvant can improve the immune response which the composition elicits; alternatively, by including an adjuvant it is possible for the compositions to have a relatively lower amount of antigen while nevertheless having immunogenicity which is comparable to unadjuvanted combination vaccines.

Combination vaccines with serogroup B meningococcus and D/T/P

The invention provides immunogenic compositions comprising (a) a capsular saccharide antigen from serogroup C of, and (b) a chitosan adjuvant. The composition preferably comprises (c) one or more further antigens and/or (d) one or more further adjuvants. The compositions are particularly suitable for mucosal delivery, including intranasal delivery. The invention also provides immunogenic compositions for mucosal delivery comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of. It is preferred that the capsular saccharides in the compositions of the invention are conjugated to carrier protein(s) and/or are oligosaccharides. Conjugated oligosaccharide antigens are particularly preferred. 

Mucosal vaccines with chitosan adjuvant and meningococcal antigens

Growing community of inventors

Siena, Italy

Barbara Baudner